Journal profile · Medicine-Oncology
Journal of Oncology Pharmacy Practice
ISSN 1078-1552 · eISSN 1477-092X · SAGE Publications Ltd · ENGLAND
Journal of Oncology Pharmacy Practice: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.27; hybrid open access; APC about USD 4,150; review about 86 days (submission to acceptance, publisher); acceptance rate 37.1% (journal website); 227 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Journal of Oncology Pharmacy Practice is published by SAGE Publications Ltd and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Safe Handling of Antineoplastic Drugs, Cancer Treatment and Pharmacology and Pharmaceutical Practices and Patient Outcomes, together about 23% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy … | View full journal description This journal is a member of the Committee on Publication Ethics (COPE).
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Barry R GoldspielPublisher website
Editorial board by country: none in mainland China; most named United States 9, United Kingdom 5, Canada 4, Germany 2, Hong Kong, China 1 (27 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Safe Handling of Antineoplastic DrugsHealth Professions10%
- Cancer Treatment and PharmacologyMedicine6.8%
- Pharmaceutical Practices and Patient OutcomesMedicine6.2%
- Chemotherapy-related skin toxicityMedicine6.2%
- Medication Adherence and ComplianceMedicine5.8%
- Neutropenia and Cancer InfectionsMedicine5.2%
- Cancer Immunotherapy and BiomarkersMedicine5.2%
- Pharmaceutical studies and practicesMedicine5.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.27LetPub ·
- Impact factor (publisher)
- 1.3Publisher website ·
- 5-year impact factor (publisher)
- 1.3Publisher website ·
- CiteScore 2026-06
- 2.7LetPub ·
- SJR 2026-06
- 0.43LetPub ·
- SNIP 2026-06
- 0.59LetPub ·
- h-index
- 28LetPub ·
- h-index
- 56OpenAlex ·
- i10-index
- 958OpenAlex ·
- 2-year mean citedness
- 1.04OpenAlex ·
- Self-citation rate
- 15.4%LetPub ·
- Share of gold OA articles
- 11.49%LetPub ·
Volume
- Articles per year
- 205LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 3,556 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 227 | 61 | 31 |
| 2025 | 227 | 67 | 204 |
| 2024 | 203 | 81 | 447 |
| 2023 | 259 | 88 | 989 |
| 2022 | 289 | 38 | 1,482 |
| 2021 | 288 | 37 | 1,801 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
86 dayssubmission to acceptance
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Acceptance rate (publisher)
- 37.1%Publisher website ·
- Submission to acceptance
- 86 daysPublisher website ·
- Acceptance to publication
- 22 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,150 / GBP 3,043 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare2 items from the author guidelines
- Reference style
- Vancouver
- Suggested reviewers
- Required
Article types accepted14
- case reportManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- case reports/seriesCase Reports/Series. The Journal of Oncology Pharmacy Practice (JOPP) prefeLength not stated
- commentaryManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- editorialManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- letters to the editorManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- original research articleManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- original research articlesOriginal Research Articles. Articles should include a clear statement of purpose; a brief historical review; and a description of the methods, procedures, subje…Length not stated
- original research paperManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- perspectiveManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- practice guidelinesPractice Guidelines. Institutional policies on medication use with outcome indicators.Length not stated
- practice issuesPractice Issues. Reports of innovative services, policies, or outcome measure tools.Length not stated
- reviewManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- review articleManuscripts are considered for publication with the understanding that they have not been published previously and are not under consideration by another public…Length not stated
- review articlesReview Articles. Comprehensive and critical reviews of drug use in cancer patient care.Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, Publication ethics, Open access, Peer review, Plagiarism, Preprints, Trial registration / reporting guidelines
- Authorship Authorship
Please view our authorship policies, which includes information on criteria for authorship, who should be the corresponding author and more. Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.
Source ↗Publisher website ·- Data availability Data availability
The Journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages. Subject to appropriate ethical and legal considerations, authors are encouraged to: Share your research data in a relevant public data repository Include a data ava…
Source ↗Publisher website ·- Publication ethics Ethical considerations
Please include your ethics approval statements under this heading, even if you have already included ethics approval information in your methods section. If ethical approval was not required, you need to explicitly state this. All papers reporting studies involving human participants, human data or human tissue must state that the relevant Ethics Committee or Institutional Review Board approved th…
Source ↗Publisher website ·- Open access Publishing fees and open access
There are no fees payable to submit or publish in this journal. Optional open access publishing is available for a fee via the Sage Choice program, and Open Access agreements, where authors can publish open access either discounted or free of charge depending on the agreement with Sage. Find out if your institution is participating by visiting Open Access Agreements at Sage. Open Access agreement …
Source ↗Publisher website ·- Peer review Peer review policy
Double anonymized peer review Model summary
The following summary describes the peer review process for this journal: Identity transparency: Double-anonymized Reviewer interacts with: Editor Review information published: None Your manuscript will undergo an initial evaluation. If it does not conform to the requirements laid out in these guidelines, it will be returned to you for amendments prior to peer review. Manuscripts may be desk rejec…
Source ↗Publisher website ·- Plagiarism Plagiarism
The journal and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. Please read Sage's complete policy on plagiarism and the actions we may take.
Source ↗Publisher website ·- Preprints Preprints
The journal will consider submissions of manuscripts that have been posted on preprint servers. Please enter the preprint DOI in the designated field when submitting your manuscript. We advise that you inform the Journal Editorial office about your posted preprint at submission. Note that you should not post an updated version of your manuscript on a preprint server while it is being peer reviewed…
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical trial registration
The journal conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first participant enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- SAGE Publications Ltd
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 1078-1552
- Electronic ISSN
- 1477-092X
- Society / sponsor
- International Society for Oncology Pharmacy … |
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Journal of Oncology Pharmacy Practice
What CAS zone is Journal of Oncology Pharmacy Practice in?
In the 2025 upgraded edition of the CAS Journal Ranking, Journal of Oncology Pharmacy Practice is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Journal of Oncology Pharmacy Practice?
The latest impact factor listed by LetPub is 1.27; CiteScore 2.7, h-index 56.
How long does peer review take at Journal of Oncology Pharmacy Practice?
The publisher reports about 86 days (submission to acceptance); the journal's website gives an acceptance rate of 37.1%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Journal of Oncology Pharmacy Practice?
According to the journal's author guidelines: Reference style: Vancouver; Suggested reviewers: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Journal of Oncology Pharmacy Practice based?
Of the 27 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (9), United Kingdom (5) and Canada (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Journal of Oncology Pharmacy Practice?
According to LetPub and DOAJ records, Journal of Oncology Pharmacy Practice is indexed in SCIE and Scopus.
Is Journal of Oncology Pharmacy Practice open access, and what is the APC?
Journal of Oncology Pharmacy Practice is a hybrid journal. For open-access publication: APC about USD 4,150.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .